NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
50 trialsNCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03705351 2024-03-04
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
Phase 1 Terminated
NCT03190967 2023-10-11
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT00582075 2023-03-27
RAD0102
University of Alabama at Birmingham
Phase 2 Completed
NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01120639 2021-08-06
Tx-Treatment
Stanford University
Phase 1/2 Completed
NCT00528437 2021-07-08
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Phase 2 Completed
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT00050986 2020-09-22
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT01402063 2020-02-17
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Brown University
Phase 2 Completed
NCT01014767 2019-08-20
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Phase 3 Terminated
NCT00826241 2019-03-22
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01044966 2019-02-12
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Medical University of South Carolina
Phase 1/2 Terminated
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077207 2018-05-16
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
Children's Oncology Group
Phase NA Completed
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00782756 2018-02-06
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT01342757 2018-01-29
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase NA Completed
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00638963 2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT02039778 2017-06-05
STRONG
Beth Israel Medical Center
Phase NA Terminated
NCT00362817 2017-06-01
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00302159 2016-08-18
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01105702 2016-08-04
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NYU Langone Health
Phase 2 Terminated
NCT00498927 2016-02-29
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00026494 2016-01-18
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02343081 2015-04-02
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
Monte Verde SA
Phase 4 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00597402 2014-05-07
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
Phase 2 Completed
NCT00575887 2013-12-20
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Marmara University
Phase 2 Completed
NCT00613028 2013-07-16
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Duke University
Phase 2 Completed
NCT00597493 2013-06-24
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Duke University
Phase 2 Completed
NCT00939991 2013-06-24
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Duke University
Phase 1/2 Completed
NCT01015534 2013-05-08
Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT00512798 2012-10-02
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT00717275 2012-10-01
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
University of Florida
Phase 2 Terminated
NCT00504660 2012-01-11
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
Phase 2 Completed